Sells cell-analysis instruments, reagents and support services to pharmaceutical and biotechnology companies, research institutions, contract research organizations and clinical laboratories.
10-K for FY2025, filed Feb 26, 2026Our FSP cell analyzers, the Cytek Aurora™, Northern Lights™, and Cytek Aurora Evo systems, deliver high-resolution, high-content and…View ↗
Since our first U.S. commercial launch in mid-2017, we have sold and deployed our instruments to customers around the world, including…View ↗
We distribute our products through our direct sales force and support organizations located in North America, Europe, China and several…View ↗
Customers pay for instrument systems and accessories when they ship. Service contracts are billed upfront and cover service over the contract term; installation and repair services are billed as delivered.
10-K for FY2025, filed Feb 26, 2026The Company’s product revenue consists of sales of its instrument systems and accessories. The Company recognizes product revenue at the…View ↗
The Company’s service revenue primarily consists of post-warranty service contracts, installations and repairs, which are recognized over…View ↗
Invoicing for products occurs upon shipment and is adjusted based on the applicable International Commercial Terms, and payment terms are…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$201.5M
10-K for FY2025, filed Feb 26, 2026
$201.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
72%
FY2022: 91%
|
Product, FY2025
$144.2M Sources
|
Sold outright |
|
Service
Mix
10-K for FY2025, filed Feb 26, 2026 |
28%
FY2022: 9.4%
|
Service, FY2025
$57.3M Sources
|
Mix |
Academic and government institutions, pharmaceutical and biotechnology companies, contract research organizations, and clinical laboratories buy through Cytek's direct sales teams in many regions; distributors and sales agents serve other markets.
10-K for FY2025, filed Feb 26, 2026
No. It lost $66.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$6.1MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 24, 2026
On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict…View ↗
8-K, filed Aug 5, 2026
Updates full year 2026 total revenue guidance to $207 million to $212 million, raising the midpoint by $1 millionView ↗
Growing. Revenue grew 57% in 4 years, from $128M in FY2021 to $201.5M in FY2025, about 12% a year.
Paid digital licenses
The latest report describes paid annual licenses and paid tiers for Cytek Cloud, a monetized digital ecosystem not described in the older report.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026We are a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical…View ↗
In addition to these workflow‑enhancing tools, we expanded the Cytek Cloud ecosystem with the introduction of Quote Builder, a tool…View ↗
Broader instrument portfolio
The latest report includes conventional flow and image-based instruments under the Amnis and Guava brands alongside the FSP portfolio; the older report's business description centers on FSP instruments.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 26, 2026In addition to our FSP product portfolio, pursuant to an acquisition in February 2023, we offer conventional flow and image-based flow…View ↗
Loading...